Respiratory Syncytial Virus (RSV) Therapeutics Market Segmentation by Drugs Type - Palivizumab, Ribavirin; Dosage Form - Oral, Injectable; Distribution Channel - Drug stores and Retail Pharmacies, Hospital Pharmacies, and Forecast 2017-2025
Sr. No. Chapter 1 Chapter 2 Chapter 3 Chapter 4 Chapter 5 Chapter 6 Chapter 7 Chapter 8 Chapter 9 Chapter 10 Chapter 11 Chapter 12 Chapter 13 Chapter 14 Content Preface Assumptions and Research Methodology Market Overview Market Dynamics Global Respiratory Syncytial Virus (RSV) Therapeutics Market Analysis and Forecasts, By Software Type Global Respiratory Syncytial Virus (RSV) Therapeutics Market Analysis, by Modality Global Respiratory Syncytial Virus (RSV) Therapeutics Market Analysis, by Application Global Respiratory Syncytial Virus (RSV) Therapeutics Market Analysis, by End-user Global Respiratory Syncytial Virus (RSV) Therapeutics Market Analysis and Forecast by Region Europe Respiratory Syncytial Virus (RSV) Therapeutics Market Analysis and Forecast Asia Pacific Respiratory Syncytial Virus (RSV) Therapeutics Market Analysis and Forecast Latin America Respiratory Syncytial Virus (RSV) Therapeutics Market Analysis and Forecast Middle East & Africa Respiratory Syncytial Virus (RSV) Therapeutics Market Analysis and Forecast Competition Landscape
Respiratory syncytial virus (RSV) is a common and contagious virus that infects the respiratory tract of children and adults. A RSV infection can lead to serious problems such as bronchiolitis and pneumonia. According to the Center for Disease and Prevention, around 25-40 of every 100 children exposed to RSV infection for the first time develop signs of bronchiolitis or pneumonia. RSV is spread from respiratory secretions through close contact with infected persons. RSV does not usually occur until a baby is 4 to 6 week old. No specific approved drug or vaccine has been available to treat or prevent RSV infection till date.
The global respiratory syncytial virus (RSV) therapeutics market is anticipated to reach more than US$ 2100.0 Mn by 2025. Respiratory syncytial virus (RSV) therapeutics market is projected to expand at a CAGR of more than 11.0% from 2017 to 2025 Increasing interest of different biotechnology companies to develop various recombinant drugs to treat RSV infection to fuel the global respiratory syncytial virus (RSV) therapeutics market from 2017 to 2025.
Biologics provide ample opportunities for players operating in the global respiratory syncytial virus (RSV) therapeutics market. Recent ongoing developments in biologic anti respiratory syncytial virus (RSV) drugs such as GlaxoSmithKline s GSK 3003891A, ReViral Ltd RV521, Bavarian Nordic s MVA-BN-RSV uncovers the potential of these drugs. Key Players such as AstraZeneca plc, and AbbVie, Inc. are Likely to Lead the Global Respiratory Syncytial Virus (RSV) Therapeutics Market.
To know more about us, please visit our website www.transparencymarketresearch.com For sales queries or new topics email us on: sales@transparencymarketresearch.com Thank You